The STAT guide to viral vectors, the linchpin of gene therapyPublished: Dec. 2019 Gene therapies were once dismissed as too dangerous to introduce to the treatment landscape. But today they are making a comeback with hundreds of products in the pipeline and under trial. In this report, we dive into the science, and business, of viral vector technologies. We spoke with executives from 18 companies to identify the pipeline of therapies that are nearing the clinic, the engineering and production challenges that